Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 22, 2026, 8:49 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 3049–3072 of 3,669 matching trials from the live ClinicalTrials.gov search.
Conditions
Leukemia
Interventions
topotecan hydrochloride
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 20 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1996
U.S. locations
27
States / cities
Birmingham, Alabama • Little Rock, Arkansas • La Jolla, California + 22 more
Conditions
B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma, Central Nervous System Lymphoma, Intraocular Lymphoma, Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System, Recurrent Adult Diffuse Large Cell Lymphoma, Retinal Lymphoma
Interventions
Dexamethasone, Laboratory Biomarker Analysis, Pharmacological Study, Pomalidomide
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
7
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Boston, Massachusetts + 4 more
Conditions
Mantle-Cell Lymphoma
Interventions
Ixazomib, Ibrutinib
Drug
Lead sponsor
PrECOG, LLC.
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
14
States / cities
Atlanta, Georgia • Augusta, Georgia • Urbana, Illinois + 11 more
Conditions
Relapsed/Refractory Aggressive B-cell Lymphomas
Interventions
MEDI-551 12 mg/kg, MEDI0680 2.5 mg/kg, MEDI0680 10 mg/kg
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 99 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
6
States / cities
Birmingham, Alabama • Baltimore, Maryland • St Louis, Missouri + 3 more
Conditions
Lymphoma, Neuroblastoma, Brain Tumor, Solid Tumor
Interventions
CUDC-907
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
1 Year to 21 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
4
States / cities
San Francisco, California • Boston, Massachusetts • Philadelphia, Pennsylvania + 1 more
Conditions
Lymphoma, Non-Hodgkins
Interventions
Ofatumumab and Bortezomib
Drug
Lead sponsor
Brown University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
3
States / cities
Hanover, New Hampshire • Providence, Rhode Island
Conditions
Metastatic Small Cell Lung Cancer
Interventions
Aldoxorubicin, Topotecan
Drug
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
11
States / cities
Los Angeles, California • Pasadena, California • Fleming Island, Florida + 8 more
Conditions
Leukemia, Lymphoma
Interventions
nelarabine
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
16 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
91
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 60 more
Conditions
Mantle-Cell Lymphoma
Interventions
Rituximab, Bortezomib,Y90 ibritumomab tiuxetan
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Hodgkin Lymphoma With no Available Curative Treatment Options Who Have a Limited Prognosis
Interventions
RNA anti-CD19 CAR T cells
Biological
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Relapsed/Refractory Multiple Myeloma
Interventions
Cevostamab
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Lung Cancer
Interventions
bortezomib, docetaxel
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 120 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
21
States / cities
Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 15 more
Conditions
Leukemia, Myeloid, Acute
Interventions
Cytarabine, Idasanutlin, Placebo
Drug · Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
447 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
7
States / cities
Great Neck, New York • Hawthorne, New York • New York, New York + 3 more
Conditions
Multiple Myeloma
Interventions
Linvoseltamab, Daratumumab, Carfilzomib, Lenalidomide, Bortezomib, Pomalidomide, Isatuximab, Fianlimab, Cemiplimab, Nirogacestat, Cevostamab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
317 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2032
U.S. locations
13
States / cities
La Jolla, California • Atlanta, Georgia • Indianapolis, Indiana + 9 more
Conditions
B-cell Non-Hodgkin Lymphoma
Interventions
AZD4512, Surovatamig
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
8
States / cities
Irvine, California • Jacksonville, Florida • Rochester, Minnesota + 4 more
Conditions
Relapsed Acute Myelogenous Leukemia
Interventions
Clofarabine, Etoposide, Cyclophosphamide, Filgrastim, Cytarabine
Drug
Lead sponsor
Therapeutic Advances in Childhood Leukemia Consortium
Other
Eligibility
1 Year to 21 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
4
States / cities
Los Angeles, California • Miami, Florida • Chicago, Illinois + 1 more
Conditions
Diffuse Large B-cell Lymphoma
Interventions
Epcoritamab, Investigator's Choice Chemotherapy
Biological · Drug
Lead sponsor
Genmab
Industry
Eligibility
18 Years and older
Enrollment
483 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
15
States / cities
Indianapolis, Indiana • Lexington, Kentucky • Jackson, Michigan + 10 more
Conditions
Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
Interventions
Biospecimen Collection, Computed Tomography, Cyclophosphamide, Fludarabine, Leukapheresis, Positron Emission Tomography, Tisagenlecleucel, Total-Body Irradiation
Procedure · Drug · Biological + 1 more
Lead sponsor
Nathan Denlinger
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Classical Hodgkin Lymphoma Recurrent, Classical Hodgkin Lymphoma Refractory, Primary Mediastinal Large B-cell Lymphoma Recurrent, Primary Mediastinal Large B-cell Lymphoma Refractory
Interventions
Pembrolizumab (+) Berahyaluronidase alfa
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
4
States / cities
Iowa City, Iowa • Waukee, Iowa • Las Vegas, Nevada + 1 more
Conditions
Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma
Interventions
Velcade, Rituximab
Drug
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Chronic Lymphocytic Leukemia (CLL), Leukaemia, Lymphocytic, Chronic
Interventions
Ofatumumab, Bendamustine
Biological · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
6
States / cities
Tuscon, Arizona • Aurora, Colorado • Fort Myers, Florida + 3 more
Conditions
Myeloid Malignancies
Interventions
Dexamethasone, Cyclophosphamide, Fludarabine, Decitabine, TGFBR2 KO CAR27/IL-15 NK cells
Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 80 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Houston, Texas
Conditions
Neuroblastoma
Interventions
Nivolumab, Ch14.18/CHO
Drug
Lead sponsor
University Hospital Southampton NHS Foundation Trust
Other
Eligibility
1 Year to 99 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2026
U.S. locations
1
States / cities
Madison, Wisconsin
Conditions
Relapsed or Refractory Mantle Cell Lymphoma
Interventions
Ibrutinib
Drug
Lead sponsor
Janssen Biotech, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
44
States / cities
Phoenix, Arizona • Duarte, California • Los Angeles, California + 41 more